Migraine is one of the most prevalent and disabling neurological conditions worldwide, affecting approximately 1 billion people globally and 12–15% of the South African adult population. Most migraine sufferers have episodic disease — attacks on fewer than 15 days per month — managed with over-the-counter or prescription triptans and oral preventive medication at modest cost. However, a subset progress to chronic migraine — defined as headache on 15 or more days per month, with features of migraine on at least 8 of those days. Chronic migraine drives substantially higher medical aid costs and introduces the possibility of CGRP monoclonal antibody therapy — a class of biologics that has transformed preventive treatment but carries an annual cost of R60,000–R80,000.
Episodic vs Chronic: The Cost Bifurcation
Episodic migraine (fewer than 15 headache days/month): Managed with triptans for acute attacks and oral preventive agents (topiramate, amitriptyline, propranolol, valproate). Annual cost: R8,000–R25,000 depending on attack frequency and specialist input. Low-to-medium cost profile; no biologic risk.
Chronic migraine (15+ headache days/month): Requires more intensive preventive therapy. CGRP monoclonal antibodies (fremanezumab, erenumab, galcanezumab) or botulinum toxin injections are the preferred preventive treatments. Annual biologic cost: R60,000–R80,000. Significant financial escalation.
What Is Chronic Migraine?
Chronic migraine develops through a process of chronification — episodic migraine becomes more frequent, often triggered by overuse of acute medications (medication overuse headache/MOH). Key clinical features:
- Headache on 15+ days per month for more than 3 months
- At least 8 days per month with migraine-quality headache
- Significant disability — migraine is the leading cause of disability in people under 50
- Common triggers: disrupted sleep, hormonal fluctuations (particularly perimenstrual), stress, weather changes, dietary factors, caffeine withdrawal
Diagnosis requires exclusion of secondary headache causes (red flags: thunderclap onset, first-ever severe headache, progressive headache, new neurological symptoms — these warrant urgent investigation including CT/MRI).
Oral Preventive Medications
For both episodic and chronic migraine, oral preventive therapy is first-line. These are inexpensive and available through standard benefits:
Topiramate (Topamax, generics): Monthly cost ~R300–R400. Most commonly used; effective; side effects include cognitive slowing and weight loss.
Amitriptyline (low dose, nocte): Monthly cost ~R100–R150. Inexpensive; good evidence for migraine prevention; also helps with sleep. Preferred in patients with comorbid depression.
Propranolol: Monthly cost ~R100–R200. Beta-blocker; good evidence; avoid in asthma or bradycardia.
Sodium valproate: Monthly cost ~R250–R350. Highly effective; teratogenic — important prescribing restrictions apply in women of childbearing potential in SA. Confirm current SAHPRA prescribing requirements.
Venlafaxine (SNRI): Modest evidence; useful where comorbid anxiety or depression is present.
CGRP Monoclonal Antibodies: The Biologic Option
Three CGRP (calcitonin gene-related peptide) monoclonal antibodies are available:
- Fremanezumab (Ajovy): Monthly or quarterly subcutaneous injection. Monthly equivalent cost: ~R5,500.
- Erenumab (Aimovig): Monthly subcutaneous injection. Monthly cost: ~R5,500.
- Galcanezumab (Emgality): Monthly subcutaneous injection. Monthly cost: ~R5,500.
CGRP mAbs are the most effective preventive therapy available for chronic migraine. In clinical trials, they reduce monthly headache days by 50% or more in approximately 50–60% of patients. Self-administered at home by subcutaneous injection.
SA SAHPRA registration status for CGRP mAbs requires verification (noted as a pending verification flag). Availability and scheme exceptional-needs pathways vary.
To get a CGRP mAb funded, your neurologist must submit an exceptional-needs application: - Confirmed chronic migraine diagnosis (15+ days/month, 3+ months) - Documentation of failure of at least two oral preventive agents at adequate doses and duration (typically 3 months each) - Monthly headache frequency and disability score (MIDAS or HIT-6) - Proposed CGRP mAb, dose, and administration schedule
Botulinum Toxin (Botox) for Chronic Migraine
OnabotulinumtoxinA (Botox) injected at 31 standardised sites across the scalp, forehead, neck, and shoulders every 12 weeks is a well-evidenced treatment specifically for chronic migraine (PREEMPT protocol). Administered by a neurologist or headache specialist in rooms. Cost per session: approximately R6,000–R9,000 for the Botox product plus R2,000–R4,000 neurologist procedure fee. Three sessions per year: total R24,000–R39,000. Exceptional-needs authorisation typically required for the Botox product.
Annual Cost Estimates
| Scenario | Estimated Annual Cost |
|---|---|
| Episodic migraine — triptans + GP/neurologist review | R8,000 – R20,000 |
| Episodic migraine on oral preventive — topiramate or amitriptyline | R10,000 – R25,000 |
| Chronic migraine — oral preventives + neurologist | R15,000 – R35,000 |
| Chronic migraine — Botox every 12 weeks | R30,000 – R60,000 |
| Chronic migraine — CGRP mAb (fremanezumab/erenumab/galcanezumab) | R60,000 – R80,000 |
Gap Cover Relevance: Medium
Chronic migraine rarely requires hospitalisation. The primary cost exposure is medication (CGRP mAbs or Botox) and specialist neurologist consultation shortfalls. Gap cover is relevant for neurologist shortfalls but is not the dominant financial planning factor — biologic medication cost and exceptional-needs coverage is the primary concern.
Plan Selection: Key Questions
- Is there an exceptional-needs pathway for CGRP monoclonal antibodies? What step-therapy is required?
- How are Botox (PREEMPT protocol) injections covered — procedure fee, product, or both?
- Is the neurologist specialist consultation benefit adequate for quarterly review (required on Botox protocol)?
- What is the monthly triptan quantity limit, and is it adequate for high-frequency episodic migraine?
Talk to Eldon
See which plans pay for chronic migraine →
This page is general information about medical schemes. It is not medical advice: speak to a healthcare professional about your own treatment. Medical aid and gap cover advice is given by Eldon de Waal, a Supervised Representative of Approach Administration (FSP 23579).